OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
23 Diciembre 2024 - 3:00AM
OBI Pharma, Inc. (OBI), a clinical-stage global oncology company
specialized in the development of novel cancer therapies such as
antibody-drug conjugates (ADC) and active immunotherapies (4174.
TWO), and GlyTech, Inc. (GlyTech), a Japan manufacturer that
focuses on glycan production and chemical glycosylation
technologies, have entered into a Marketing Agreement and a
Material Transfer Agreement.
Under the terms of the Marketing Agreement, OBI grants GlyTech
rights to market and promote OBI’s GlycOBI® ADC enabling
technologies, powered by EndoSymeOBI®, to potential pharma and
biotech partners in Japan. GlyTech will also be a key supplier of
glycans in Japan. Under the terms of the Material Transfer
Agreement, OBI will transfer some of its cutting-edge materials to
GlyTech for research in advancing the efficient production of
glycans for ADCs.
Heidi Wang, Ph.D., OBI Pharma’s Chief Executive Officer, noted,
“GlyTech has been one of our trusted suppliers for high quality
glycans. We are excited to collaborate with GlyTech to broaden the
reach of OBI’s novel GlycOBI® ADC enabling technologies with
potential pharma and biotech partners in Japan. We also look
forward to the collaborative research with GlyTech, which is part
of our plan to ensure high quality, scalable glycan manufacturing
and supply for ADCs.”
Hiroaki Asai, President & CEO of GlyTech, added, “OBI
Pharma's innovative GlycOBI® ADC technologies are testaments to
their command of enzyme-based precision synthetic organic
chemistry. GlyTech, Inc. is pleased to support the contribution of
GlycOBI® ADC technologies to the world as a supplier of highly pure
human glycans, a key material for this technology. We greatly look
forward to OBI Pharma's continuing progress in new drug
development.”
About OBI Pharma, Inc.
OBI Pharma, Inc., is a clinical stage global oncology company
that is headquartered in Taiwan and established in 2002. Its
mission is to develop novel cancer therapeutic agents for patients
with high unmet medical needs.
Using the company’s proprietary ADC enabling technologies,
including but not limited to GlycOBI®, powered by EndoSymeOBI®, OBI
has created its novel ADC pipeline, including OBI-992, OBI-902 and
OBI-904, targeting TROP2 and Nectin-4, respectively. Additionally,
the company’s novel first-in-class immuno-oncology portfolio
targeting Globo H includes: two Globo H active immunotherapy
vaccines, adagloxad simolenin (formerly OBI-822) and OBI-833. OBI’s
pipeline also includes the first-in-class AKR1C3-targeted
small-molecule prodrug OBI-3424, which selectively releases a
potent DNA-alkylating antitumor agent in the presence of the
aldo-keto reductase 1C3 (AKR1C3) enzyme that is highly expressed in
tumors. Additional information can be found
at www.obipharma.com.
GlycOBI® and EndoSymeOBI® are registered trademarks of OBI
Pharma, Inc.
About GlyTech, Inc.
GlyTech, Inc. is headquartered in Kyoto, Japan and was
established in 2012 as the only bio-venture company in the world
capable of the commercial production of human-type glycans. Its
current mission is to contribute to efforts enabling people to live
healthier lives by supporting the development of advanced products
and technologies that take advantage of glycans, proteins,
nucleotides and other naturally occurring biochemicals.
GlyTech’s technology platforms include the glycan-based
enhancement of drugs of various modalities, brain drug delivery
technology, and peptide binder discovery services. GlyTech’s own
pipeline contains several assets that utilize glycans, and the
company is conducting investigator-initiated clinical trials (P2a)
for a glycosylated somatostatin with acromegaly as the target
indication.
Additional information can be found at www.glytech-inc.com/
COMPANY CONTACT:Kevin
PoulosChief Business OfficerOBI
Pharma, Inc.1.619.537.7698 Ext.
102kpoulos@obipharmausa.com
http://www.obipharma.com/
https://www.linkedin.com/company/obi-pharma-inc
https://twitter.com/obipharma?lang=en